Since the study concerns patients assessed between 2012 and 2020, only a small percentage of the patients taking renin–angiotensin system inhibitors were under angiotensin receptor neprilysin inhibitors; in addition, no patients were using sodium glucose transporter inhibitors for HF treatment. The gene discussed is REN; the disease is hydrops fetalis.